Circulating Tumor DNA Predicts Recurrence in Esophageal Cancer
Assessing circulating tumor DNA (ctDNA) in patients with esophageal squamous cell carcinoma (ESCC) identifies high recurrence risk after surgery.
Newsletter
Upper Gastrointestinal Tract
Every new paper in this field, in your inbox.
Survival Advantage with Neoadjuvant Chemotherapy in Esophageal Cancer
Neoadjuvant chemotherapy (NCT) significantly improves long-term survival in patients with esophageal and esophagogastric junction adenocarcinoma compared to chemoradiotherapy (NCRT).
Log Odds of Lymph Nodes Enhance Risk Prediction Post-Esophagectomy
Researchers found that the log odds of positive lymph nodes significantly improve risk stratification for early recurrence after radical esophagectomy in cT3 esophageal squamous cell carcinoma.
Surgery for Gastroesophageal Junction Cancers May Be Omitted
New data raises the question of whether surgery can be skipped for certain gastric and gastroesophageal junction cancers with high pathologic complete response rates.
Novel Approach in Gastric Cancer: Clean-Net Technique Study
The Clean-Net technique shows promising long-term outcomes for select gastric cancer patients.
Comparison of Pocket-Creation and Conventional Methods in ESD
Pocket-creation method (PCM) is a noninferior option to conventional endoscopic submucosal dissection (ESD) for gastric tumors, with lower subsequent surgery rates.
Revision Rates in Robotic Hiatal Hernia Repair: Key Insights
Larger hiatal hernias substantially increase the risk of revision after robotic repair, informing surgical decision-making.
Type 2 Diabetes Increases Risks in Esophagectomy Patients
Type 2 diabetes significantly worsens outcomes after minimally invasive esophagectomy for esophageal squamous cell carcinoma.
Fragility of NCCN Guidelines for Gastric Cancer Treatment
Recent analysis reveals significant concerns in the quality of evidence supporting NCCN guidelines for gastric cancer treatment.
Survival Advantage in Esophageal Cancer: FLOT vs CROSS
Patients with esophageal adenocarcinoma achieving pathological complete response show better outcomes with FLOT chemotherapy compared to CROSS chemoradiotherapy.